ES2621188T3 - Péptidos terapéuticos - Google Patents
Péptidos terapéuticos Download PDFInfo
- Publication number
- ES2621188T3 ES2621188T3 ES10784830.1T ES10784830T ES2621188T3 ES 2621188 T3 ES2621188 T3 ES 2621188T3 ES 10784830 T ES10784830 T ES 10784830T ES 2621188 T3 ES2621188 T3 ES 2621188T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- amino acid
- molecular weight
- exact mass
- log
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title description 6
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract description 10
- 239000000816 peptidomimetic Substances 0.000 abstract description 8
- 125000004122 cyclic group Chemical group 0.000 abstract description 7
- 238000006467 substitution reaction Methods 0.000 abstract description 7
- 239000004599 antimicrobial Substances 0.000 abstract description 3
- 150000001576 beta-amino acids Chemical class 0.000 abstract description 3
- 230000001461 cytolytic effect Effects 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
- 150000003862 amino acid derivatives Chemical class 0.000 abstract 2
- -1 aminopropyl Chemical group 0.000 description 35
- 210000003743 erythrocyte Anatomy 0.000 description 28
- 230000001093 anti-cancer Effects 0.000 description 26
- 230000000845 anti-microbial effect Effects 0.000 description 18
- 241000588724 Escherichia coli Species 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 206010041925 Staphylococcal infections Diseases 0.000 description 16
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 16
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 14
- 230000001988 toxicity Effects 0.000 description 14
- 231100000419 toxicity Toxicity 0.000 description 14
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 9
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 8
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 229960003085 meticillin Drugs 0.000 description 4
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- DWUKPZRHBMSEBP-UHFFFAOYSA-N n-[(3,5-dimethylphenyl)methyl]propanamide Chemical compound CCC(=O)NCC1=CC(C)=CC(C)=C1 DWUKPZRHBMSEBP-UHFFFAOYSA-N 0.000 description 2
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical class CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- QSKDCDXNVDSXTJ-UHFFFAOYSA-N 2-(aminomethyl)-1-(4-methylpiperazin-1-yl)-3-[4-(trifluoromethyl)phenyl]-2-[[4-(trifluoromethyl)phenyl]methyl]propan-1-one Chemical compound C1CN(C)CCN1C(=O)C(CN)(CC=1C=CC(=CC=1)C(F)(F)F)CC1=CC=C(C(F)(F)F)C=C1 QSKDCDXNVDSXTJ-UHFFFAOYSA-N 0.000 description 1
- OEQPLOLNYDYFAD-UHFFFAOYSA-N 2-(aminomethyl)-1-(4-methylpiperazin-1-yl)-3-naphthalen-2-yl-2-(naphthalen-2-ylmethyl)propan-1-one Chemical compound C1CN(C)CCN1C(=O)C(CN)(CC=1C=C2C=CC=CC2=CC=1)CC1=CC=C(C=CC=C2)C2=C1 OEQPLOLNYDYFAD-UHFFFAOYSA-N 0.000 description 1
- SZKYSLMCLAOCLE-UHFFFAOYSA-N 2-(aminomethyl)-1-(4-methylpiperazin-1-yl)-5-phenyl-2-(3-phenylpropyl)pentan-1-one Chemical compound C1CN(C)CCN1C(=O)C(CN)(CCCC=1C=CC=CC=1)CCCC1=CC=CC=C1 SZKYSLMCLAOCLE-UHFFFAOYSA-N 0.000 description 1
- UQKYBWXIHPGHQG-UHFFFAOYSA-N 2-(aminomethyl)-2-benzyl-N-[2-(dimethylamino)ethyl]-3-phenylpropanamide Chemical compound NCC(C(=O)NCCN(C)C)(CC1=CC=CC=C1)CC1=CC=CC=C1 UQKYBWXIHPGHQG-UHFFFAOYSA-N 0.000 description 1
- IHDMGHIWRBSLNB-UHFFFAOYSA-N 2-(aminomethyl)-3-(3,5-dimethylphenyl)-2-[(3,5-dimethylphenyl)methyl]-1-(4-methylpiperazin-1-yl)propan-1-one Chemical compound C1CN(C)CCN1C(=O)C(CN)(CC=1C=C(C)C=C(C)C=1)CC1=CC(C)=CC(C)=C1 IHDMGHIWRBSLNB-UHFFFAOYSA-N 0.000 description 1
- FXTFNKKEUSXQQA-UHFFFAOYSA-N 2-(aminomethyl)-3-(4-tert-butylphenyl)-2-[(4-tert-butylphenyl)methyl]-1-(4-methylpiperazin-1-yl)propan-1-one Chemical compound C1CN(C)CCN1C(=O)C(CN)(CC=1C=CC(=CC=1)C(C)(C)C)CC1=CC=C(C(C)(C)C)C=C1 FXTFNKKEUSXQQA-UHFFFAOYSA-N 0.000 description 1
- WJZDIPVFXFOKAD-UHFFFAOYSA-N 2-(aminomethyl)-n-[2-(dimethylamino)ethyl]-3-[4-(trifluoromethyl)phenyl]-2-[[4-(trifluoromethyl)phenyl]methyl]propanamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1CC(CN)(C(=O)NCCN(C)C)CC1=CC=C(C(F)(F)F)C=C1 WJZDIPVFXFOKAD-UHFFFAOYSA-N 0.000 description 1
- GSZCLKHYJBMCHT-UHFFFAOYSA-N 2-(aminomethyl)-n-[2-(dimethylamino)ethyl]-5-phenyl-2-(3-phenylpropyl)pentanamide Chemical compound C=1C=CC=CC=1CCCC(CN)(C(=O)NCCN(C)C)CCCC1=CC=CC=C1 GSZCLKHYJBMCHT-UHFFFAOYSA-N 0.000 description 1
- 125000006186 3,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C([H])=C1C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 1
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- AHSHQVINSCWCMT-UHFFFAOYSA-N C1=CC=C(C=C1)CCC(CC(CN)C2=CC=CC=C2)C(=O)NCCN Chemical compound C1=CC=C(C=C1)CCC(CC(CN)C2=CC=CC=C2)C(=O)NCCN AHSHQVINSCWCMT-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- GKUKXYDPDYIORP-UHFFFAOYSA-N n-(2-aminoethyl)-2-(aminomethyl)-2-propylpentanamide Chemical compound CCCC(CN)(CCC)C(=O)NCCN GKUKXYDPDYIORP-UHFFFAOYSA-N 0.000 description 1
- SMKGPOBRXVODMK-UHFFFAOYSA-N n-(2-aminoethyl)-2-(aminomethyl)-4-cyclohexyl-2-(2-cyclohexylethyl)butanamide Chemical compound C1CCCCC1CCC(CN)(C(=O)NCCN)CCC1CCCCC1 SMKGPOBRXVODMK-UHFFFAOYSA-N 0.000 description 1
- JVOZATDVXUSPKC-UHFFFAOYSA-N n-(2-aminoethyl)-2-(aminomethyl)-5-phenyl-2-(3-phenylpropyl)pentanamide Chemical compound C=1C=CC=CC=1CCCC(CN)(C(=O)NCCN)CCCC1=CC=CC=C1 JVOZATDVXUSPKC-UHFFFAOYSA-N 0.000 description 1
- SOGZMDYBQZTXIJ-UHFFFAOYSA-N n-(cyclohexylmethyl)propanamide Chemical compound CCC(=O)NCC1CCCCC1 SOGZMDYBQZTXIJ-UHFFFAOYSA-N 0.000 description 1
- DCWXCLSGSDNKGX-UHFFFAOYSA-N n-(naphthalen-2-ylmethyl)propanamide Chemical compound C1=CC=CC2=CC(CNC(=O)CC)=CC=C21 DCWXCLSGSDNKGX-UHFFFAOYSA-N 0.000 description 1
- VRBPVCCMUXYKQU-UHFFFAOYSA-N n-[(3,5-dimethoxyphenyl)methyl]propanamide Chemical compound CCC(=O)NCC1=CC(OC)=CC(OC)=C1 VRBPVCCMUXYKQU-UHFFFAOYSA-N 0.000 description 1
- OSTGXTASNHUYFX-UHFFFAOYSA-N n-[(3,5-ditert-butylphenyl)methyl]propanamide Chemical compound CCC(=O)NCC1=CC(C(C)(C)C)=CC(C(C)(C)C)=C1 OSTGXTASNHUYFX-UHFFFAOYSA-N 0.000 description 1
- NXEHUVBLMTVJGJ-UHFFFAOYSA-N n-[(4-methylphenyl)methyl]propanamide Chemical compound CCC(=O)NCC1=CC=C(C)C=C1 NXEHUVBLMTVJGJ-UHFFFAOYSA-N 0.000 description 1
- VOUJNJOXQSJIKB-UHFFFAOYSA-N n-[(4-propan-2-ylphenyl)methyl]propanamide Chemical compound CCC(=O)NCC1=CC=C(C(C)C)C=C1 VOUJNJOXQSJIKB-UHFFFAOYSA-N 0.000 description 1
- WJSVLIMLQVTJDD-UHFFFAOYSA-N n-[(4-tert-butylphenyl)methyl]propanamide Chemical compound CCC(=O)NCC1=CC=C(C(C)(C)C)C=C1 WJSVLIMLQVTJDD-UHFFFAOYSA-N 0.000 description 1
- RFBIIXCJFYHQCT-UHFFFAOYSA-N n-[[4-(trifluoromethyl)phenyl]methyl]propanamide Chemical compound CCC(=O)NCC1=CC=C(C(F)(F)F)C=C1 RFBIIXCJFYHQCT-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0919194 | 2009-11-02 | ||
| GBGB0919194.1A GB0919194D0 (en) | 2009-11-02 | 2009-11-02 | Compounds |
| PCT/GB2010/002024 WO2011051692A1 (en) | 2009-11-02 | 2010-11-02 | Therapeutic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2621188T3 true ES2621188T3 (es) | 2017-07-03 |
Family
ID=41435032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10784830.1T Active ES2621188T3 (es) | 2009-11-02 | 2010-11-02 | Péptidos terapéuticos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8809280B2 (enExample) |
| EP (1) | EP2496596B1 (enExample) |
| JP (1) | JP5810090B2 (enExample) |
| KR (1) | KR101730680B1 (enExample) |
| CN (1) | CN102762586B (enExample) |
| AU (1) | AU2010311186B2 (enExample) |
| BR (1) | BR112012010333A2 (enExample) |
| CA (1) | CA2777749C (enExample) |
| DK (1) | DK2496596T3 (enExample) |
| ES (1) | ES2621188T3 (enExample) |
| GB (1) | GB0919194D0 (enExample) |
| NZ (1) | NZ599791A (enExample) |
| PL (1) | PL2496596T3 (enExample) |
| RU (2) | RU2548905C2 (enExample) |
| WO (1) | WO2011051692A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3974563A1 (en) | 2011-12-28 | 2022-03-30 | Chugai Seiyaku Kabushiki Kaisha | Cyclic peptides |
| JP7020910B2 (ja) | 2015-03-13 | 2022-02-16 | 中外製薬株式会社 | 改変アミノアシルｔＲＮＡ合成酵素およびその用途 |
| GB201601868D0 (en) | 2016-02-02 | 2016-03-16 | Lytix Biopharma As | Methods |
| CN109071600A (zh) * | 2016-04-14 | 2018-12-21 | 道健康生活医药株式会社 | 淀粉样蛋白球体（aspd）结合抑制肽以及评价和筛选方法 |
| WO2018143145A1 (ja) | 2017-01-31 | 2018-08-09 | 中外製薬株式会社 | 無細胞翻訳系におけるペプチドの合成方法 |
| GB201705255D0 (en) * | 2017-03-31 | 2017-05-17 | Univ I Tromsø - Norges Arktiske Univ | Bioactive cyclic compounds |
| WO2018188761A1 (en) | 2017-04-13 | 2018-10-18 | Lytix Biopharma As | Method of reducing population size of tregs and/or mdscs |
| US11542299B2 (en) | 2017-06-09 | 2023-01-03 | Chugai Seiyaku Kabushiki Kaisha | Method for synthesizing peptide containing N-substituted amino acid |
| JP7411414B2 (ja) | 2017-12-15 | 2024-01-11 | 中外製薬株式会社 | ペプチドの製造方法、及び塩基の処理方法 |
| KR20250119653A (ko) | 2018-11-07 | 2025-08-07 | 추가이 세이야쿠 가부시키가이샤 | O-치환 세린 유도체의 제조 방법 |
| EP3889164A4 (en) | 2018-11-30 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR DEPROTECTION AND METHOD FOR RESIN REMOVAL IN A SOLID PHASE REACTION OF A PEPTIDE COMPOUND OR AN AMIDE COMPOUND, AND METHOD FOR PRODUCTION OF A PEPTIDE COMPOUND |
| JP7472101B2 (ja) | 2019-03-15 | 2024-04-22 | 中外製薬株式会社 | 芳香族アミノ酸誘導体の製造方法 |
| CN110294793B (zh) * | 2019-06-24 | 2023-10-27 | 合肥科生景肽生物科技有限公司 | Sumo荧光探针及其制备方法 |
| JP6880352B1 (ja) | 2019-11-07 | 2021-06-02 | 中外製薬株式会社 | Ｋｒａｓ阻害作用を有する環状ペプチド化合物 |
| CN114790151B (zh) * | 2022-02-14 | 2023-03-31 | 湖南省湘中制药有限公司 | 一种2-氰基-2-丙戊酸甲酯的复合催化制备方法 |
| KR20250122523A (ko) | 2022-12-20 | 2025-08-13 | 리틱스 바이오파마 에이에스 | 종양 용해성 펩티드 및 키토산을 포함하는 조성물 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342705A (en) | 1979-11-23 | 1982-08-03 | Monsanto Company | Methylene thioethers |
| AU565221B2 (en) | 1982-06-03 | 1987-09-10 | Montedison S.P.A. | 2-(1,2,4-triazol-1-yl) propanone derivatives |
| IT1161927B (it) | 1983-03-31 | 1987-03-18 | Montedison Spa | Furano-derivati ad attivita' fungicida |
| DK523288A (da) | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| CA1328333C (en) | 1988-03-04 | 1994-04-05 | Quirico Branca | Amino acid derivatives |
| CA2088195A1 (en) | 1990-08-31 | 1992-03-01 | David C. Horwell | Cholecystokinin antagonists, their preparation and therapeutic use |
| US5593967A (en) | 1990-08-31 | 1997-01-14 | Warner-Lambert Company | Cholecystokinin antagonists, their preparation and therapeutic use |
| US5387671A (en) * | 1990-12-27 | 1995-02-07 | Abbott Laboratories | Hexa- and heptapeptide anaphylatoxin-receptor ligands |
| US5885782A (en) | 1994-09-13 | 1999-03-23 | Nce Pharmaceuticals, Inc. | Synthetic antibiotics |
| CZ297544B6 (cs) | 1996-01-02 | 2007-02-07 | Aventis Pharmaceuticals Inc. | Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy |
| US6323227B1 (en) | 1996-01-02 | 2001-11-27 | Aventis Pharmaceuticals Products Inc. | Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| US6080767A (en) | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
| DE102006018080A1 (de) | 2006-04-13 | 2007-10-18 | Aicuris Gmbh & Co. Kg | Lysobactinamide |
| JP5322108B2 (ja) * | 2006-07-10 | 2013-10-23 | ペーベーアードライ ビオメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗菌ペプチド |
| GB0724951D0 (en) * | 2007-12-20 | 2008-01-30 | Lytix Biopharma As | Compounds |
| ATE482186T1 (de) * | 2008-03-18 | 2010-10-15 | Univ Dresden Tech | Modulares gerüst zur gestaltung von spezifischen molekülen zur verwendung als pepitmimetika und hemmer für die proteininteraktion |
-
2009
- 2009-11-02 GB GBGB0919194.1A patent/GB0919194D0/en not_active Ceased
-
2010
- 2010-11-02 WO PCT/GB2010/002024 patent/WO2011051692A1/en not_active Ceased
- 2010-11-02 BR BR112012010333A patent/BR112012010333A2/pt active IP Right Grant
- 2010-11-02 NZ NZ599791A patent/NZ599791A/en unknown
- 2010-11-02 US US13/505,625 patent/US8809280B2/en active Active
- 2010-11-02 CA CA2777749A patent/CA2777749C/en active Active
- 2010-11-02 JP JP2012535924A patent/JP5810090B2/ja active Active
- 2010-11-02 RU RU2012121264/04A patent/RU2548905C2/ru active
- 2010-11-02 AU AU2010311186A patent/AU2010311186B2/en active Active
- 2010-11-02 EP EP10784830.1A patent/EP2496596B1/en active Active
- 2010-11-02 DK DK10784830.1T patent/DK2496596T3/en active
- 2010-11-02 RU RU2015111706A patent/RU2676713C2/ru active
- 2010-11-02 PL PL10784830T patent/PL2496596T3/pl unknown
- 2010-11-02 KR KR1020127014266A patent/KR101730680B1/ko active Active
- 2010-11-02 CN CN201080049560.6A patent/CN102762586B/zh active Active
- 2010-11-02 ES ES10784830.1T patent/ES2621188T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2496596T3 (en) | 2017-04-03 |
| EP2496596A1 (en) | 2012-09-12 |
| JP2013509389A (ja) | 2013-03-14 |
| CA2777749C (en) | 2019-08-06 |
| GB0919194D0 (en) | 2009-12-16 |
| JP5810090B2 (ja) | 2015-11-11 |
| RU2015111706A3 (enExample) | 2018-10-29 |
| RU2548905C2 (ru) | 2015-04-20 |
| US20130035296A1 (en) | 2013-02-07 |
| KR20120104986A (ko) | 2012-09-24 |
| BR112012010333A2 (pt) | 2016-03-29 |
| AU2010311186B2 (en) | 2015-09-24 |
| RU2676713C2 (ru) | 2019-01-10 |
| RU2012121264A (ru) | 2013-12-10 |
| WO2011051692A1 (en) | 2011-05-05 |
| CN102762586A (zh) | 2012-10-31 |
| CN102762586B (zh) | 2016-10-05 |
| PL2496596T3 (pl) | 2017-08-31 |
| AU2010311186A1 (en) | 2012-05-31 |
| US8809280B2 (en) | 2014-08-19 |
| KR101730680B1 (ko) | 2017-04-26 |
| NZ599791A (en) | 2014-10-31 |
| RU2015111706A (ru) | 2015-11-10 |
| EP2496596B1 (en) | 2017-01-11 |
| CA2777749A1 (en) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2621188T3 (es) | Péptidos terapéuticos | |
| ES2972577T3 (es) | Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP) | |
| ES2262567T3 (es) | Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico. | |
| ES2435000T3 (es) | Aminoácidos anticonvulsionantes para el tratamiento del dolor | |
| ES2545219T3 (es) | Fragmentos de péptido para inducir la síntesis de las proteínas de la matriz extracelular | |
| ES2544573T3 (es) | Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor | |
| ES2594706T3 (es) | Péptidos biológicamente activos | |
| ES2633989T3 (es) | Formulación líquida estable de amg 416 (velcalcetida) | |
| US20090062186A1 (en) | Compounds Binding To P-Selectin | |
| WO2013184794A2 (en) | Peripheral kappa receptor agonists for reducing pain and inflammation | |
| EP2139523A2 (en) | Binding ligand linked drug delivery conjugates of tubulysins | |
| ES2553770T3 (es) | Inhibidores de apoptosis y usos de los mismos | |
| EP4021476A1 (en) | Synthetic antimicrobial peptides | |
| US20250325469A1 (en) | Inhibitors of atp synthase - cosmetic and therapeutic uses | |
| ES2405323T3 (es) | Tratamiento de melanoma | |
| US20150139907A1 (en) | Calcium-binding agents induce hair growth and/or nail growth | |
| ES2607986T3 (es) | Agentes terapéuticos para regular el fósforo en suero | |
| ES2377808T3 (es) | Péptidos antibacterianos | |
| US20090176705A1 (en) | Modular platform for targeted therapeutic delivery | |
| ES2965807T3 (es) | Combinación de temozolomida y un conjugado de PAR-1 para tratar el glioblastoma | |
| WO2002024192A1 (fr) | Ligands dipeptidiques du recepteur npff pour le traitement de la douleur et des hyperalgies | |
| ES2998053T3 (en) | Linear lipopeptide paenipeptins and methods of using the same | |
| ES3005857T3 (en) | Novel peptoids and use thereof for preventing or treating chronic pain | |
| ES2654489T3 (es) | Péptido cíclico y producto farmacéutico que lo contiene | |
| HK1128234A1 (en) | Combination comprising combretastatin and anticancer agents |